Abstract
The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this Nacylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.
Keywords: Glial cells, N-acylethanolamine, neuroprotection, spinal cord
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
Volume: 12 Issue: 1
Author(s): Emanuela Esposito and Salvatore Cuzzocrea
Affiliation:
Keywords: Glial cells, N-acylethanolamine, neuroprotection, spinal cord
Abstract: The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this Nacylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.
Export Options
About this article
Cite this article as:
Esposito Emanuela and Cuzzocrea Salvatore, Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010010
DOI https://dx.doi.org/10.2174/1871527311312010010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crimean-Congo Hemorrhagic Fever Virus
Current Molecular Medicine Relationship Between Oxidative Stress, Tau Level and Antioxidant Mechanisms of the KEAP-1/NRF-2/HO-1 in Children with Hydrocephalus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Small Molecule Inhibitors of Peptidylprolyl cis/trans Isomerase
Current Enzyme Inhibition Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Kolaviron, A Biflavonoid Compound: Its Pharmacological Activity and Therapeutic Efficacy
Current Bioactive Compounds Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Ceftriaxone and Phenylalanine Combination as Broad Spectrum Antimicrobials Therapy
Current Drug Therapy GPE and GPE Analogues as Promising Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Cornel Iridoid Glycoside Suppresses Tau Hyperphosphorylation and Aggregation in a Mouse Model of Tauopathy through Increasing Activity of PP2A
Current Alzheimer Research RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke
Current Neurovascular Research Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Adult Hippocampal Neurogenesis as Target for the Treatment of Depression
CNS & Neurological Disorders - Drug Targets Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage
Current Pharmaceutical Design Therapeutic Proteins for Treatment of Corneal Epithelial Defects
Current Medicinal Chemistry Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Use of Human Umbilical Cord Blood (HUCB) Cells to Repair the Damaged Brain
Current Neurovascular Research Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Polymeric Nanomicelles of Soluplus® as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds
Current Nanomedicine PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design